Xgeva (2010) is indicated for the treatment of a significantly smaller patient population , i.e., for the prevention of SRE in solid tumor and multiple myeloma patients, giant cell tumor of bone, and hypercalcemia in patients refractory to bisphosphonate therapies
Get the same active ingredients, personalized dosing, and lower cost, without compromising quality or results
Subgroup analysis for treatment durations 6 months indicated a higher WL in the GLP-1RAs group (SMD = 0.79, 95% CI 0.25 to 1.34)
Q:Are you products effective and safe
Individual results vary based on starting weight, dose, adherence, diet, and physical activity
The primary outcome of this pilot study was the induction of an anticancer proteome response at the end of 4th week during 4-week intermittent fasting and 1 week after 4-week intermittent fasting